// App-Quantinova.ai

2991 : Inhibition of Rac1 GTPase activity by SH7139, a new drug candidate for non-Hodgkin's lymphoma targeting HLA-DR10

Researchers

Presenter

  • Rodney Balhorn

Principal Investigators

  • Arjan J. van Adrichem

  • Saphon Hok

  • Monique C. Balhorn

Medical Centers

  • SHAL Technologies, Inc., Livermore, CA.

  • University of Helsinki, H, Finland

  • Lawrence Livermore National Laboratory, Livermore, CA

Locations

  • United States

  • Finland

Companies

  • SHAL Technologies, I

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Non-Hodgkin's Lymphoma

  • Burkitt lymphoma

  • Non‐Hodgkin Lymphoma

  • Lymphomas

  • Solid malignancies

Biomarkers

  • N/A

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • N/A

Phase

  • II

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved